A Randomized, Double-blind, Placebo Controlled Phase III Study of Darolutamide (ODM-201) Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer
收藏DataCite Commons2026-01-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009353/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide
(ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in
patients with metastatic hormone sensitive prostate cancer.
提供机构：
Vivli
创建时间：
2023-10-11
